Chemkart India IPO

Chemkart India IPO is a book-built issue worth ₹80.08 crore. The IPO comprises a fresh issue of 26.00 lakh equity shares aggregating to ₹64.48 crore and an offer for sale of 6.29 lakh equity shares worth ₹15.60 crore. The IPO opens for subscription on July 7, 2025, and closes on July 9, 2025. The allotment is expected to be finalised on July 10, 2025, with tentative listing on BSE SME scheduled for July 14, 2025.

The IPO is priced in a band of ₹236 – ₹248 per share. Retail investors must apply for a minimum of 2 lots comprising 1,200 shares, requiring an investment of ₹2,97,600 at the cutoff price. HNI investors must apply for a minimum of 3 lots (1,800 shares), amounting to ₹4,46,400.

Smart Horizon Capital Advisors Private Limited is the book-running lead manager to the issue, and Bigshare Services Private Limited is the registrar. Alacrity Securities Ltd. is acting as the market maker for the IPO.

For detailed information on company financials, business operations, and associated risks, investors are advised to refer to the Chemkart India IPO RHP.

Industry Outlook

1. India’s nutraceutical sector is growing rapidly, fuelled by rising health awareness, higher incomes, urbanisation, and a shift towards preventive care. More people are turning to nutritional supplements to manage lifestyle-related health issues.
2. Chemkart India Limited operates in this expanding market, offering a wide range of products such as amino acids, herbal extracts, vitamins, proteins, and sports nutrition. The industry remains fragmented, with both organised and unorganised players affected by regional demand-supply trends. Chemkart stands out through competitive pricing, economies of scale, and quality assurance via third-party testing.
3. Competition is intensifying, with global and domestic firms vying for share. Chemkart’s B2B focus—supplying raw materials for health and sports supplements, positions it as a reliable partner for manufacturers. Its in-house blending and grinding capabilities allow custom formulations, strengthening its client offering.
4. Government initiatives like “Make in India” and stricter FSSAI regulations are pushing the industry towards greater formalisation. Companies delivering quality, supply chain efficiency, and innovation are set to lead the next phase of growth.

Chemkart India IPO Objectives

The company proposes to utilise the net proceeds from the IPO for the following objectives:

1. Set up a dedicated nutraceutical manufacturing unit through ERMPL in the JNPA SEZ, including land purchase, construction, and equipment installation to boost exports and enable backward integration.
2. Repay or prepay existing borrowings to reduce interest costs, strengthen the balance sheet, and improve financial flexibility.
3. Fund general corporate needs such as brand building, administrative expenses, and strategic initiatives to grow market presence and improve efficiency.
4. Strengthen corporate governance and visibility by listing on the BSE SME platform, thus enhancing investor trust and enabling any future capital access and partnerships.

About Chemkart India Limited

Chemkart India Limited was originally incorporated as Chemkart India Private Limited on 6 March 2020 under the Companies Act, 2013. The company was subsequently converted into a public limited entity and renamed Chemkart India Limited on 4 October 2024, following resolutions passed by its Board and shareholders.

Headquartered in Mumbai, Maharashtra, Chemkart is engaged in the processing and trading of nutritional and health supplements. The company operates primarily in the B2B segment, supplying raw materials used in the manufacture of finished products such as sports supplements, vitamins, proteins, and herbal extracts. Its product portfolio spans seven key categories: amino acids, health supplements, herbal extracts, nucleotides, proteins, sports nutrition, and vitamins.

Chemkart maintains a warehouse and processing facility in Bhiwandi, Thane, covering approximately 28,259 square feet. This facility is equipped with blending and grinding machinery capable of processing up to 990 metric tonnes annually, enabling the company to offer customised formulations tailored to client specifications.

In September 2024, Chemkart acquired 99% stakes in Easy Raw Materials Private Limited and Vinstar Biotech Private Limited, marking its strategic entry into backward integration. Through its wholly owned subsidiary ERMPL, the company plans to establish a manufacturing unit within the Jawaharlal Nehru Port Authority (JNPA) Special Economic Zone, further enhancing its production capabilities and export potential.

How To Check the Allotment Status of the Chemkart India IPO?

Steps to check IPO allotment status on Angel One’s app:

1. Log in to the Angel One app.
2. Go to the IPO Section and then to IPO Orders.
3. Select the individual IPO that you had applied for and check the allotment status.
4. Angel One will notify you of your IPO allotment status via push notification and email.

How To Apply for Chemkart India IPO Online?

1. Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
2. Locate the IPO Section: Navigate to the 'IPO' section on the platform.
3. Select IPO: Find and select the Chemkart India IPO from the list of open IPOs.
4. Enter the Lot Size: Specify the number of lots you want to bid for.
5. Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
6. Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.

Contact Details of Chemkart India IPO

Registered Office: Office No. 403/404, 4th Floor, K.L. Accolade, 6th Road, TPS III, Santacruz (East), Mumbai – 400055, Maharashtra, India.

Phone: +91 91363 83828
E-mail: investors@chemkart.com

Chemkart India IPO Reservation

Chemkart India IPO Lot Size

Chemkart India IPO Promoter Holding

The promoters of the company are Mr. Ankit Shaileesh Mehta, Ms. Parul Shaileesh Mehta, and Mr. Shaileesh Vinodrai Mehta.

Know before investing

Strengths

8

1. Offers seven categories of nutraceutical ingredients including amino acids, proteins, and herbal extracts.

2. Investment in a manufacturing facility through its wholly owned subsidiary enhances control over production and quality.

3. Strong foothold in the raw material supply chain for health and sports supplement manufacturers.

4. Equipped with blending and grinding machinery for customised formulations.

5. Warehouse located in Bhiwandi and upcoming SEZ unit in JNPA, Mumbai, supports efficient logistics and export potential.

6. Demonstrated consistent revenue and profit growth over the last three financial years.

7. Operates in a growing nutraceutical sector driven by rising health awareness and preventive healthcare trends.

8. Funds allocated for manufacturing infrastructure, debt reduction, and brand development to fuel long-term growth.

Risks

8

1. Heavy reliance on top suppliers without long-term contracts may disrupt supply continuity.

2. Significant procurement from China poses risks due to international trade tensions and regulatory shifts.

3. Short track record in trading and manufacturing may affect investor confidence and forecasting accuracy.

4. Major revenue derived from Maharashtra, Gujarat, and Delhi increases vulnerability to regional economic shifts.

5. The company’s logo is not yet registered, exposing it to potential intellectual property disputes.

6. Past delays in statutory filings and tax returns may attract penalties or regulatory scrutiny.

7. Outstanding unsecured borrowings from promoters could be recalled at short notice, impacting liquidity.

8. Wholly owned subsidiaries have reported losses, which may affect consolidated financial performance.